Expertise in
4
conditions

Dr. Harold Bays

Endocrinology
Office
3288 Illinois Ave, 
Louisville, KY 
Expertise in
4
conditions
Office
3288 Illinois Ave, 
Louisville, KY 

Overview

Harold Bays is an Endocrinologist in Louisville, Kentucky. Dr. Bays is highly rated in 4 conditions, according to our data. His top areas of expertise are Obesity, Familial Hypertriglyceridemia, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

His clinical research consists of co-authoring 229 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Endocrinology

Licenses

Internal Medicine in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Office
3288 Illinois Ave, Louisville, KY 40213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity With and Without Prediabetes
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity With and Without Prediabetes
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
Enrollment Status: Completed
Publish Date: April 24, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 11 Less Clinical Trials

229 Total Publications

Correction: Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.
Correction: Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.
Journal: International journal of obesity (2005)
Published: November 13, 2025
Similar Doctors
Expertise in
68
conditions
Dr. Vasdev Lohano
Endocrinology
Expertise in
68
conditions
Dr. Vasdev Lohano
Endocrinology

Daniel P. Akin M.D. FACS Inc

2019 State St, 
New Albany, IN 
 (6.2 miles away)
812-949-5700
Languages Spoken:
English
See accepted insurances

Vasdev Lohano is an Endocrinologist in New Albany, Indiana. Dr. Lohano is highly rated in 68 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Hyperthyroidism, Thyroid Storm, and Thyroid Nodule.

Expertise in
16
conditions
Dr. Hisham Alrefai
Endocrinology
Expertise in
16
conditions
Dr. Hisham Alrefai
Endocrinology

Associates In Infectious Diseases PSC

9720 Park Plaza Ave Unit 104, 
Louisville, KY 
 (9.9 miles away)
502-895-8218
Languages Spoken:
English
See accepted insurances

Hisham Alrefai is an Endocrinologist in Louisville, Kentucky. Dr. Alrefai is highly rated in 16 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Type 1 Diabetes (T1D), and Hypothyroidism.

Expertise in
44
conditions
Dr. Derick Adams
Endocrinology
Expertise in
44
conditions
Dr. Derick Adams
Endocrinology

Baptist Health Medical Group Endocrinology

2800 Breckenridge Ln Ste 320, 
Louisville, KY 
 (7.3 miles away)
502-895-4263
Languages Spoken:
English
See accepted insurances

Derick Adams is an Endocrinologist in Louisville, Kentucky. Dr. Adams is highly rated in 44 conditions, according to our data. His top areas of expertise are Melorheostosis with Osteopoikilosis, Osteoporosis, Postmenopausal Osteoporosis, and Melorheostosis.

Frequently Asked Questions about Dr. Harold Bays

How do I make an appointment with Dr. Harold Bays?

You can book an appointment with Dr. Harold Bays by calling their office at 502-515-6621. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Harold Bays a top-rated expert for Obesity?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Harold Bays is classified as an Elite expert for Obesity, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Harold Bays specialize in?

While Dr. Harold Bays is a Endocrinology, they have specific expertise in Obesity, Familial Hypertriglyceridemia, and Type 2 Diabetes (T2D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Harold Bays participate in research or clinical trials?

Yes. Dr. Harold Bays has published 229 articles and abstracts on conditions like Obesity. You can view a list of Dr. Harold Bays's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Harold Bays accept my insurance?

Dr. Harold Bays accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 502-515-6621 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bays's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile